Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3398167 | 1.00 | NAAA (0.33) | NAAAPDE10ACHRNA7RXFP1PIK3CD | |
| SCHEMBL4859819 | 0.93 | CHRM4 (0.33) | CHRNA7CHRM4 | |
| SCHEMBL4859809 | 0.93 | CHRM4 (0.33) | CHRNA7CHRM4 | |
| SCHEMBL314941 | 0.89 | CHRNA7 (0.35) | NAAAPDE10ACHRNA7RXFP1PIK3CD | |
| SCHEMBL3399328 | 0.89 | CHRNA7 (0.35) | NAAAPDE10ACHRNA7RXFP1PIK3CD | |
| SCHEMBL315460 | 0.88 | CHRNA7 (0.32) | CHRNA7RXFP1CHRM4CYP4F2CYP4A11 | |
| SCHEMBL3401000 | 0.88 | CHRNA7 (0.32) | CHRNA7RXFP1CHRM4CYP4F2CYP4A11 | |
| SCHEMBL2142885 | 0.88 | CHRNA7 (0.44) | CHRNA7RXFP1CYP4F2CYP4A11 | |
| SCHEMBL2138931 | 0.88 | RXFP1 (0.44) | NAAACHRNA7RXFP1 | |
| SCHEMBL5275422 | 0.88 | RXFP1 (0.44) | NAAACHRNA7RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093394-B2 | Derivatives of 5-thioxylopyranose and use of same for treatment | LABORATOIRES FOURNIER S.A. (FR) | 2012-01-10 | — | — | US | disclosed |
| EP-2066683-B1 | DERIVATIVES OF 5-THIOXYLOPYRANOSE AND USE OF SAME FOR TREATMENT | FOURNIER LAB SA (FR) | 2010-11-03 | — | — | EP | disclosed |
| US-20090182013-A1 | Derivatives of 5-Thioxylopyranose and Use of Same for Treatment | LABORATOIRES FOURNIER S.A. (FR) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182013-A1 | Derivatives of 5-Thioxylopyranose and Use of Same for Treatment | TPMT, PNPO, PPOX | NAAA 2772/4885PDE10A 1836/4885CHRNA7 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.